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step uses the Risk Priority Number (RPN) which is a product of relative 
indices of occurrence, detectability and severity. 
4) Corrective re-design - process re-engineering to remove stresses 
from the system and reduce the likelihood of recurrence.  
Results: A complex process map was produced and over 40 potential 
FM's were identified in the system. RPN analysis identified 11 FM's 
which were rated sufficiently highly to initiate corrective re-design. 
This involved major initiatives such as ensuring the process was 
completely paperless, conduction of staff training sessions to promote 
independent checking and the purchase of additional equipment to 
reduce the incidence of incorrect patient set up. More minor re-design 
initiatives involved increasing the incidence of patient identification 
checks and ensuring multiple assessment of pregancy status 
throughout the process.  
Conclusions: This study has indicated that FMEA can be applied in the 
RT setting. Although an ever evolving process FMEA has identified 
scope for improving the RT process, strengthened the risk 
management matrix and enabled the evolution of a bespoke QC 
programme designed on the basis of prospective analysis and 
quantification of risk. Much further work is required in this area such 
as tighter specifications of RPN's, and a reduction in the beauracratic 
load however it is felt FMEA is a valuable and rapidly developing 
quality tool for radiotherapy.  
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Purpose/Objective: To investigate responses to clinically relevant 
radiotherapy regimens in new generation mouse models for BRCA1/2-
deficient breast cancer using a preclinical system for image-guided 
irradiation. 
Materials and Methods: Radiotherapy interventions were carried out 
using a small-animal dedicated Cone-Beam CT(CBCT) equipped micro-
irradiator. A dose-response (i.e. Tumor Control Probability, TCP) 
relationship was determined using various fractionated treatment 
regimens (i.e. 2Gy, 4Gy, 8Gy per fraction) in the BRCA1 model. In 
addition, radiosensitivity of the other models was determined. For this 
purpose, the tumors were measured by caliper and CBCT. Metastatic 
spread was investigated by CBCT and routine pathology of inner 
organs. We are currently harvesting residual and relapsing tumors that 
escaped radiotherapy control to determine whether these contain 
stably radioresistant cells. Similarly, tumor specimens of metastatic 
lesions are reimplanted and irradiated to determine the 
radiosensitivity. Ongoing assays are evaluating DNA damage and 
repair, epithelial-mesenchymal-transition (EMT) and gene expression 
profiling. 
Results: After a follow up of 6 months we observed a dose dependent 
TCP relationship. According to the Linear-Quadratic Model using 3Gy, 
the D50 and m were 84Gy and m=0.5, respectively (Fig). The optimal 
α/β ratio to recalculate the physical dose into a biologically 
equivalent dose (as given in 2 Gy per fraction) was 3 Gy. As expected, 
the BRCA1/2-deficient carcinomas were highly sensitive compared 
with the BRCA proficient carcinomas. In contrast, BRCA2-deficient 
tumors that had undergone EMT only responded moderately to 
radiotherapy. Despite their high sensitivity, most BRCA1/2-deficient 
carcinomas were not eradicated, and eventually relapsed (Fig). 
Although most recurrent tumors responded again to radiation, the 
response durations were shortened. Moreover, some recurrent tumors 
escaped radiotherapy control. As an alternative way to escape local 
radiotherapy control, we observed the occurrence of distance 
metastasis in about 20% of mice. 
 
  
Conclusions: Using dedicated preclinical image-guided irradiation 
techniques we present here that genetically engineered mouse models 
for BRCA1/2-deficient breast cancer are useful for the study of 
radiotherapy response. Our data strongly suggest that we may have a 
method to develop radiotherapy-resistant tumors which will be helpful 
to tackle the clinical problem of radiotherapy resistance. In 
particular, therapeutic approaches to increase radiosensitivity and 
prevent metastasis formation (e.g. PARP inhibitors) can be tested in 
these models. Moreover, we are investigating the role of hypoxia and 
DNA damage repair and targeted agents for radioresistance. Our hope 
is that these models may help to identify new therapeutic strategies 
that could guide clinical trials in the future.  
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Purpose/Objective: Determination of the main factors affecting the 
development of radiation reactions in the group of patients with 
chronic exposure. The possible impact of the absorbed dose received 
as a result of chronic radiation exposure associated with the activities 
of the plant 'Mayak', the incidence and severity of radiation reactions 
during radiotherapy. 
Materials and Methods: We have carried out a retrospective analysis 
of medical data of patients treated with external beam radiotherapy 
for solid tumors of various localizations. Study group comprised 89 
patients who had an indication on chronic radiation exposure history. 
182 patients of the control group prior were not been exposed to 
radiation. Patients of study and control groups were matched for age, 
sex, diagnosis and treatment. Assessment the frequency, severity of 
radiation reactions and complications was performed. 
Results: It was shown that the quantity of absorbed dose from chronic 
irradiation has no significant effect on the incidence and severity of 
radiation reactions. The frequency of radiation reactions did not differ 
significantly (p = 0,957): in the study group was 59.6% (53 patients), in 
the control group - 60.3% (108 patients). The distribution of reaction 
severity did not differ significantly between groups (p = 0,176). 
However, the study group was dominated by the Grade II reactions 
(64.15%), while in the control group Grade I and Grade II reactions 
distributed almost equally - 51.4% and 48.6% respectively. In some 
cases symptoms of the reactions caused the need to interrupt 
treatment. The number of breaks was significantly higher in the study 
group - 10 (11.2%) than in control - 7 patients (3.8%) (p = 0,018). 
There was statistically significant difference in the dynamics of the 
process (p =0.048), indicating a lower frequency of the positive effect 
of radiotherapy in previously irradiated patients. There were no 
statistically significant effect on the frequency of radiation reactions 
of absorbed doses to red bone marrow (CMC) (p = 0.534) and soft 
tissue (p = 0.359). The dose to the red bone marrow had no effect on 
the considered parameters: the treatment completion (p = 0.226), the 
frequency of breaks (p = 0.777), dynamics (p = 0.88). 
Conclusions: These data suggest that the main factors affecting the 
frequency of radiation reactions in cancer patients with chronic 
radiation exposure history, similar to those in patients without prior 
exposure to radiation. However, the detected changes in the severity 
of the reactions, dynamics of the process may be indicative of 
changes in radiosensitivity in patients previously exposed to chronic 
irradiation. Incorporation of these features in the radiotherapy 
planning will help to optimize a treatment plan, to reduce the 
incidence and severity of reactions, thereby improving the quality of 
life in cancer patients.  
